Determination of R(+)- and S(-)-lansoprazole using chiral stationary-phase liquid chromatography and their enantioselective pharmacokinetics in humans

Pharmaceutical Research

Volumn 13, Issue 4, 1996, Pages 611-615

  Katsuki, Hisakazu ^a   Yagi, Hatsumi ^a   Arimori, Kazuhiko ^a   Nakamura, Chizuko ^a   Nakano, Masahiro ^a   Katafuchi, Shigeru ^b   Fujioka, Yuhichi ^b   Fujiyama, Shigetoshi ^b  

^a KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Chiral separation; Enantiomer; Lansoprazole; Metabolic ratio

Indexed keywords

LANSOPRAZOLE;

ADULT; ARTICLE; CHIRALITY; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG PROTEIN BINDING; ENANTIOMER; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; STEREOSPECIFICITY; VOLUNTEER;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADMINISTRATION, ORAL; ADULT; BLOOD PROTEINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENZYME INHIBITORS; FEMALE; H(+)-K(+)-EXCHANGING ATPASE; HUMANS; MALE; MICROSOMES, LIVER; OMEPRAZOLE; PROTEIN BINDING; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TABLETS;

EID: 0029944431     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016062508580     Document Type: Article

References (12)

1. J. Caldwell. The importance of stereochemistry in drug action and disposition. J. Clin. Pharmacol. 32:925-929 (1992).
2. T. Uematsu, M. Nakano, K. Kosuge, A. Nagai, A. Sato, and M. Nakashima. Pharmacokinetic properties of a novel gastric proton pump inhibitor, (±)-2-[(4-methoxy-6,7,8,9-tetrahydro-5H-cyclohepta [b] pyridin-9-yl)sulfinyl] -1H-benzimidazole sodium salt, in healthy subjects. J. Pharm. Sci. 83:1407-1411 (1994).
3. D. E. Drayer. Pharmacodynamic and pharmacokinetic differences between drug enantiomers in humans: An overview. Clin. Pharmacol. Ther. 40:125-133 (1986).
4. G. S. Nerurkar, S. V. Dighe, and R. L. Williams. Bioequivalence of racemic drugs. J. Clin. Pharmacol. 32:935-943 (1992).
5. K. Miwa, M. Mitani, T. Tsukamoto, K. Yoshida, T. Kobayashi, T. Kimura, H. Simomura, and S. Tanayama. Metabolic fate of AG-1749, a new proton pump inhibitor, in rats, mice, and dogs. Jpn. Pharmacol. Ther. 18:3413-3435 (1990).
6. I. Aoki, M. Okumura, and T. Yashiki. High-performance liquid chromatographic determination of lansoprazole and its metabolites in human serum and urine. J. Chromatogr. 571:283-290 (1990).
7. Y. Imamura, K. Iwamoto, Y. Yanachi, T. Higuchi, and M. Otagiri. Postnatal development, sex-related difference and hormonal regulation of acetohexamide reductase activities in rat liver and kidney. J. Pharmacol. Exp. Ther. 264:166-171 (1993).
8. O. H. Lowry, A. L. Rosebrough, A. L. Farr, and R. J. Randall. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:265-275 (1951).
9. M. Eichelbaum, G. Mikus, and B. Vogelgesang. Pharmacokinetics of (+), (-), and (±) verapamil after intravenous administration. Br. J. Clin. Pharmacol. 17:453-458 (1984).
10. B. Delhotal Landes, J. P. Petite, and B. Flouvat. Clinical pharmacokinetics of lansoprazole. Clin. Pharmacokinet. 28:458-470 (1995).
11. R. Mehvar, J. M. Reynolds, M. A. Robinson, and J. A. Longstreth. Enantioselective kinetics of verapamil and norverapamil in isolated perfused rat livers. Pharm. Res. 11:1815-1819 (1994).
12. M. Tateno, and N. Nakamura. Phase I study of lansoprazole (AG-1749) antiulcer agent - Capsule form -. Rinsho Iyaku 7:51-62 (1991).